AGE-RELATED MACULAR DEGENERATION

This study tests a stem cell therapy called OpRegen for people with advanced dry age-related macular degeneration (geographic atrophy). Researchers inject retinal pigment epithelium cells derived from human embryonic stem cells into the eye to see if they can safely replace damag…

This study planned to test a small telescope implant inside the eye for people with severe vision loss from advanced age-related macular degeneration (AMD). The device was meant to improve central vision by magnifying images onto healthy parts of the retina. However, the trial wa…

This early-stage trial tests a one-time gene therapy injection (NG101) for wet age-related macular degeneration. The therapy uses a harmless virus to deliver a gene that makes a drug inside the eye, aiming to reduce the need for repeated anti-VEGF injections. About 20 adults aged…

This early-stage study tests the safety of an experimental drug called RO7669330, given as an injection into the eye, for people with geographic atrophy (GA) due to age-related macular degeneration (AMD). The study involves 27 participants and will monitor side effects and eye he…

This early-stage trial tests an experimental drug called Kamuvudine-8 (K8) for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 30 participants receive eye injections of K8 and are monitored for 26 weeks to check s…

This early-stage trial tests a gene therapy called KH658 for people with wet age-related macular degeneration (AMD). The treatment aims to deliver a protein that blocks abnormal blood vessel growth, potentially reducing the need for frequent eye injections. Nine participants aged…

This study follows 18 people who already received RetinoStat, a gene therapy for wet age-related macular degeneration, to see if it remains safe over time. Researchers track side effects and vision changes. The goal is to understand long-term risks, not to test if the treatment w…

This early-stage trial tests a gene therapy called KH631 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment aims to deliver a protein that blocks harmful blood vessel growth, potentially reducing the need for frequent eye inj…

This study tests whether a pre-filled syringe is as safe as the traditional vial when giving the medicine bevacizumab for certain eye diseases. About 120 people with wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion will receive inject…

This study tests a device called AVIGA that tracks eye movements to detect vision problems in people with wet age-related macular degeneration (AMD). Researchers will compare the device's results with standard eye exams to see if it can reliably spot disease activity. The goal is…

This study tests a new, high-resolution camera that takes 3D pictures of the back of the eye. It aims to see tiny details in the retina of people with age-related macular degeneration (AMD). The goal is to help doctors diagnose AMD earlier and track the disease better. About 50 a…

This study is a 5-year extension that follows people who previously took part in the AREDS or AREDS2 studies. Its purpose is to observe how age-related macular degeneration (AMD) and cataracts naturally progress over time. Participants receive yearly eye exams and are contacted b…

This study follows 400 people with intermediate age-related macular degeneration (AMD) for about 3 years. Researchers watch how the disease advances to more severe stages and test if measuring the loss of light-sensing cells in the eye can be a useful way to track the disease. No…

This study looks at a specific type of blood vessel growth (type 1 MNV) that can occur under the retina in people with age-related macular degeneration (AMD). Researchers want to find out if these vessels actually help preserve vision rather than harm it. About 73 adults aged 50 …